Drug Trial Radar · NCT05221840
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,051
Actual
Start
Feb 7, 2022
Primary completion
Jan 8, 2027
Study completion Jul 2, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.
Conditions
- Non-Small Cell Lung Cancer
Interventions
DurvalumabDrug
Durvalumab IV (intravenous infusion)
OleclumabDrug
Oleclumab IV (intravenous infusion)
MonalizumabDrug
Monalizumab IV (intravenous infusion)
PlaceboOther
Placebo IV (intravenous infusion)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Surival (PFS)Time frame: Up to 5 years after first patient randomized.
Locations
202 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
San Diego, California
Research Site
New Haven, Connecticut
Research Site
Stuart, Florida
Research Site
Urbana, Illinois
Research Site
New Albany, Indiana
Research Site
Lexington, Kentucky
Research Site
Louisville, Kentucky
Research Site
Annapolis, Maryland
Research Site
Baltimore, Maryland
Research Site
Baltimore, Maryland
Research Site
Bethesda, Maryland
Research Site
Grand Rapids, Michigan
Research Site
Duluth, Minnesota
Research Site
Billings, Montana
Research Site
Ridgewood, New Jersey
Research Site
Ithaca, New York
Research Site
Greensboro, North Carolina
Research Site
Cleveland, Ohio
Research Site
Cleveland, Ohio
Research Site
Maumee, Ohio
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
York, Pennsylvania
Research Site
Sioux Falls, South Dakota
Research Site
Houston, Texas
Research Site
Charlottesville, Virginia
Research Site
Fairfax, Virginia
Research Site
Fredericksburg, Virginia
Research Site
Richmond, Virginia
Research Site
Richland, Washington
Research Site
Spokane, Washington
Research Site
Tacoma, Washington
Research Site
Milwaukee, Wisconsin
Research Site
Box Hill, Australia
Research Site
East Melbourne, Australia
Research Site
Elizabeth Vale, Australia
Research Site
Gosford, Australia
Research Site
Heidelberg, Australia
Research Site
Kogarah, Australia
Research Site
South Brisbane, Australia
Showing 40 of 202 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.